IMMUNITY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2214044, encodeId=e6b62214044fc, content=投了9天还没消息是好消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb82411870, createdName=1237a2bem44(暂无昵称), createdTime=Tue Jul 09 11:35:03 CST 2024, time=2024-07-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1182151, encodeId=4eee1182151e9, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;感染;基础免疫 经验分享：免疫学研究型期刊大概如下：第一档，Cell，Nature，Science第二档，Cell子刊Immunity，这几年上升势头很快，IF也超过了Nature immunology；Nature子刊Nature immunology，这几年IF有所下降，不过不失为免疫性方向最好的期刊之一；Nature子刊Nature medicine，若有清楚的机制研究加上潜在的临床应用，最好的选择之一。反正老板投稿顺序倾向是除CNS外， Immunity > Nature immunology> Science Immunology 第三档，Journal of Experimental Medicine，老牌偏免疫学杂志，近来IF渐行渐低，但上面的文章可一点儿也不含糊，不过这两年也更多的接受其它医学领域的研究了；Nature子刊Nature Cell Biology，不过其更偏向于经典细胞生物学，偶有偏免疫方向文章；Journal of Clinical Investigation，医学研究的老牌杂志，及Science比较新的子刊Science Translational Medicine大概也在这个档中。另外，像Journal of Allergy and Clinical Immunology、Blood、Gastroenterology也是很有实力的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c65457430, createdName=linkends353, createdTime=Sat Jan 08 10:47:10 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091785, encodeId=eddd1091e85ad, content=一般方法中要求写什么东西？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091786, encodeId=bf181091e86a9, content=一般情况下使用什么统计方法？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800296, encodeId=e986800296f2, content=22.5，超过NI了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:39:08 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=556195, encodeId=116455619575, content=Cell子刊.免疫学大佬.很难.不过感觉有些组做上手了后还是发了很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e502075746, createdName=营养医师, createdTime=Fri May 18 22:05:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544479, encodeId=49855444e902, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500353, encodeId=5d975003536c, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：Immunity这个杂志比 C N S这三大杂志来得更客观些，更看重你的工作本身；只要你的工作确实够有新意并且数据比较系统，他们就会选择把你的文章送出去review，后面三个杂志很看重author的分量，如果没有找重量级的大牛挂名，就很难有review的机会。 我的文章在这个杂志的第一次review用了一个半月（第32天的时候，所有的reviewer意见都回到editor手里，他们会考虑11天的时间，所以意见回到我手上是一个半月以后），revised重新投回去后，第二次review只等了14天，所有的意见都回到了editor手里，他们讨论了11天后才把意见返回到我手上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=774, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Dec 26 20:11:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485168, encodeId=077a48516849, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：If my problem was a Death Star, this atrlcie is a photon torpedo., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=695, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Tessa, createdTime=Mon Oct 31 18:14:00 CST 2011, time=2011-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483892, encodeId=4187483892e7, content=very difficult, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 09 22:08:00 CST 2011, time=2011-08-09, status=1, ipAttribution=)]

2024-07-09 1237a2bem44(暂无昵称) 来自安徽省

投了9天还没消息是好消息吗

21 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2214044, encodeId=e6b62214044fc, content=投了9天还没消息是好消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb82411870, createdName=1237a2bem44(暂无昵称), createdTime=Tue Jul 09 11:35:03 CST 2024, time=2024-07-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1182151, encodeId=4eee1182151e9, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;感染;基础免疫 经验分享：免疫学研究型期刊大概如下：第一档，Cell，Nature，Science第二档，Cell子刊Immunity，这几年上升势头很快，IF也超过了Nature immunology；Nature子刊Nature immunology，这几年IF有所下降，不过不失为免疫性方向最好的期刊之一；Nature子刊Nature medicine，若有清楚的机制研究加上潜在的临床应用，最好的选择之一。反正老板投稿顺序倾向是除CNS外， Immunity > Nature immunology> Science Immunology 第三档，Journal of Experimental Medicine，老牌偏免疫学杂志，近来IF渐行渐低，但上面的文章可一点儿也不含糊，不过这两年也更多的接受其它医学领域的研究了；Nature子刊Nature Cell Biology，不过其更偏向于经典细胞生物学，偶有偏免疫方向文章；Journal of Clinical Investigation，医学研究的老牌杂志，及Science比较新的子刊Science Translational Medicine大概也在这个档中。另外，像Journal of Allergy and Clinical Immunology、Blood、Gastroenterology也是很有实力的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c65457430, createdName=linkends353, createdTime=Sat Jan 08 10:47:10 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091785, encodeId=eddd1091e85ad, content=一般方法中要求写什么东西？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091786, encodeId=bf181091e86a9, content=一般情况下使用什么统计方法？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800296, encodeId=e986800296f2, content=22.5，超过NI了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:39:08 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=556195, encodeId=116455619575, content=Cell子刊.免疫学大佬.很难.不过感觉有些组做上手了后还是发了很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e502075746, createdName=营养医师, createdTime=Fri May 18 22:05:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544479, encodeId=49855444e902, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500353, encodeId=5d975003536c, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：Immunity这个杂志比 C N S这三大杂志来得更客观些，更看重你的工作本身；只要你的工作确实够有新意并且数据比较系统，他们就会选择把你的文章送出去review，后面三个杂志很看重author的分量，如果没有找重量级的大牛挂名，就很难有review的机会。 我的文章在这个杂志的第一次review用了一个半月（第32天的时候，所有的reviewer意见都回到editor手里，他们会考虑11天的时间，所以意见回到我手上是一个半月以后），revised重新投回去后，第二次review只等了14天，所有的意见都回到了editor手里，他们讨论了11天后才把意见返回到我手上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=774, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Dec 26 20:11:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485168, encodeId=077a48516849, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：If my problem was a Death Star, this atrlcie is a photon torpedo., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=695, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Tessa, createdTime=Mon Oct 31 18:14:00 CST 2011, time=2011-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483892, encodeId=4187483892e7, content=very difficult, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 09 22:08:00 CST 2011, time=2011-08-09, status=1, ipAttribution=)]

2022-01-08 linkends353

审稿速度:2.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤;感染;基础免疫
经验分享：免疫学研究型期刊大概如下：第一档，Cell，Nature，Science第二档，Cell子刊Immunity，这几年上升势头很快，IF也超过了Nature immunology；Nature子刊Nature immunology，这几年IF有所下降，不过不失为免疫性方向最好的期刊之一；Nature子刊Nature medicine，若有清楚的机制研究加上潜在的临床应用，最好的选择之一。反正老板投稿顺序倾向是除CNS外， Immunity > Nature immunology> Science Immunology
第三档，Journal of Experimental Medicine，老牌偏免疫学杂志，近来IF渐行渐低，但上面的文章可一点儿也不含糊，不过这两年也更多的接受其它医学领域的研究了；Nature子刊Nature Cell Biology，不过其更偏向于经典细胞生物学，偶有偏免疫方向文章；Journal of Clinical Investigation，医学研究的老牌杂志，及Science比较新的子刊Science Translational Medicine大概也在这个档中。另外，像Journal of Allergy and Clinical Immunology、Blood、Gastroenterology也是很有实力的期刊。

212 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2214044, encodeId=e6b62214044fc, content=投了9天还没消息是好消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb82411870, createdName=1237a2bem44(暂无昵称), createdTime=Tue Jul 09 11:35:03 CST 2024, time=2024-07-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1182151, encodeId=4eee1182151e9, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;感染;基础免疫 经验分享：免疫学研究型期刊大概如下：第一档，Cell，Nature，Science第二档，Cell子刊Immunity，这几年上升势头很快，IF也超过了Nature immunology；Nature子刊Nature immunology，这几年IF有所下降，不过不失为免疫性方向最好的期刊之一；Nature子刊Nature medicine，若有清楚的机制研究加上潜在的临床应用，最好的选择之一。反正老板投稿顺序倾向是除CNS外， Immunity > Nature immunology> Science Immunology 第三档，Journal of Experimental Medicine，老牌偏免疫学杂志，近来IF渐行渐低，但上面的文章可一点儿也不含糊，不过这两年也更多的接受其它医学领域的研究了；Nature子刊Nature Cell Biology，不过其更偏向于经典细胞生物学，偶有偏免疫方向文章；Journal of Clinical Investigation，医学研究的老牌杂志，及Science比较新的子刊Science Translational Medicine大概也在这个档中。另外，像Journal of Allergy and Clinical Immunology、Blood、Gastroenterology也是很有实力的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c65457430, createdName=linkends353, createdTime=Sat Jan 08 10:47:10 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091785, encodeId=eddd1091e85ad, content=一般方法中要求写什么东西？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091786, encodeId=bf181091e86a9, content=一般情况下使用什么统计方法？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800296, encodeId=e986800296f2, content=22.5，超过NI了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:39:08 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=556195, encodeId=116455619575, content=Cell子刊.免疫学大佬.很难.不过感觉有些组做上手了后还是发了很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e502075746, createdName=营养医师, createdTime=Fri May 18 22:05:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544479, encodeId=49855444e902, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500353, encodeId=5d975003536c, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：Immunity这个杂志比 C N S这三大杂志来得更客观些，更看重你的工作本身；只要你的工作确实够有新意并且数据比较系统，他们就会选择把你的文章送出去review，后面三个杂志很看重author的分量，如果没有找重量级的大牛挂名，就很难有review的机会。 我的文章在这个杂志的第一次review用了一个半月（第32天的时候，所有的reviewer意见都回到editor手里，他们会考虑11天的时间，所以意见回到我手上是一个半月以后），revised重新投回去后，第二次review只等了14天，所有的意见都回到了editor手里，他们讨论了11天后才把意见返回到我手上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=774, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Dec 26 20:11:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485168, encodeId=077a48516849, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：If my problem was a Death Star, this atrlcie is a photon torpedo., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=695, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Tessa, createdTime=Mon Oct 31 18:14:00 CST 2011, time=2011-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483892, encodeId=4187483892e7, content=very difficult, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 09 22:08:00 CST 2011, time=2011-08-09, status=1, ipAttribution=)]

2021-12-28 Gym璨烨

一般方法中要求写什么东西？

191 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2214044, encodeId=e6b62214044fc, content=投了9天还没消息是好消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb82411870, createdName=1237a2bem44(暂无昵称), createdTime=Tue Jul 09 11:35:03 CST 2024, time=2024-07-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1182151, encodeId=4eee1182151e9, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;感染;基础免疫 经验分享：免疫学研究型期刊大概如下：第一档，Cell，Nature，Science第二档，Cell子刊Immunity，这几年上升势头很快，IF也超过了Nature immunology；Nature子刊Nature immunology，这几年IF有所下降，不过不失为免疫性方向最好的期刊之一；Nature子刊Nature medicine，若有清楚的机制研究加上潜在的临床应用，最好的选择之一。反正老板投稿顺序倾向是除CNS外， Immunity > Nature immunology> Science Immunology 第三档，Journal of Experimental Medicine，老牌偏免疫学杂志，近来IF渐行渐低，但上面的文章可一点儿也不含糊，不过这两年也更多的接受其它医学领域的研究了；Nature子刊Nature Cell Biology，不过其更偏向于经典细胞生物学，偶有偏免疫方向文章；Journal of Clinical Investigation，医学研究的老牌杂志，及Science比较新的子刊Science Translational Medicine大概也在这个档中。另外，像Journal of Allergy and Clinical Immunology、Blood、Gastroenterology也是很有实力的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c65457430, createdName=linkends353, createdTime=Sat Jan 08 10:47:10 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091785, encodeId=eddd1091e85ad, content=一般方法中要求写什么东西？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091786, encodeId=bf181091e86a9, content=一般情况下使用什么统计方法？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800296, encodeId=e986800296f2, content=22.5，超过NI了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:39:08 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=556195, encodeId=116455619575, content=Cell子刊.免疫学大佬.很难.不过感觉有些组做上手了后还是发了很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e502075746, createdName=营养医师, createdTime=Fri May 18 22:05:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544479, encodeId=49855444e902, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500353, encodeId=5d975003536c, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：Immunity这个杂志比 C N S这三大杂志来得更客观些，更看重你的工作本身；只要你的工作确实够有新意并且数据比较系统，他们就会选择把你的文章送出去review，后面三个杂志很看重author的分量，如果没有找重量级的大牛挂名，就很难有review的机会。 我的文章在这个杂志的第一次review用了一个半月（第32天的时候，所有的reviewer意见都回到editor手里，他们会考虑11天的时间，所以意见回到我手上是一个半月以后），revised重新投回去后，第二次review只等了14天，所有的意见都回到了editor手里，他们讨论了11天后才把意见返回到我手上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=774, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Dec 26 20:11:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485168, encodeId=077a48516849, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：If my problem was a Death Star, this atrlcie is a photon torpedo., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=695, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Tessa, createdTime=Mon Oct 31 18:14:00 CST 2011, time=2011-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483892, encodeId=4187483892e7, content=very difficult, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 09 22:08:00 CST 2011, time=2011-08-09, status=1, ipAttribution=)]

2021-12-28 MS68862005

一般情况下使用什么统计方法？

201 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2214044, encodeId=e6b62214044fc, content=投了9天还没消息是好消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb82411870, createdName=1237a2bem44(暂无昵称), createdTime=Tue Jul 09 11:35:03 CST 2024, time=2024-07-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1182151, encodeId=4eee1182151e9, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;感染;基础免疫 经验分享：免疫学研究型期刊大概如下：第一档，Cell，Nature，Science第二档，Cell子刊Immunity，这几年上升势头很快，IF也超过了Nature immunology；Nature子刊Nature immunology，这几年IF有所下降，不过不失为免疫性方向最好的期刊之一；Nature子刊Nature medicine，若有清楚的机制研究加上潜在的临床应用，最好的选择之一。反正老板投稿顺序倾向是除CNS外， Immunity > Nature immunology> Science Immunology 第三档，Journal of Experimental Medicine，老牌偏免疫学杂志，近来IF渐行渐低，但上面的文章可一点儿也不含糊，不过这两年也更多的接受其它医学领域的研究了；Nature子刊Nature Cell Biology，不过其更偏向于经典细胞生物学，偶有偏免疫方向文章；Journal of Clinical Investigation，医学研究的老牌杂志，及Science比较新的子刊Science Translational Medicine大概也在这个档中。另外，像Journal of Allergy and Clinical Immunology、Blood、Gastroenterology也是很有实力的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c65457430, createdName=linkends353, createdTime=Sat Jan 08 10:47:10 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091785, encodeId=eddd1091e85ad, content=一般方法中要求写什么东西？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091786, encodeId=bf181091e86a9, content=一般情况下使用什么统计方法？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800296, encodeId=e986800296f2, content=22.5，超过NI了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:39:08 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=556195, encodeId=116455619575, content=Cell子刊.免疫学大佬.很难.不过感觉有些组做上手了后还是发了很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e502075746, createdName=营养医师, createdTime=Fri May 18 22:05:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544479, encodeId=49855444e902, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500353, encodeId=5d975003536c, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：Immunity这个杂志比 C N S这三大杂志来得更客观些，更看重你的工作本身；只要你的工作确实够有新意并且数据比较系统，他们就会选择把你的文章送出去review，后面三个杂志很看重author的分量，如果没有找重量级的大牛挂名，就很难有review的机会。 我的文章在这个杂志的第一次review用了一个半月（第32天的时候，所有的reviewer意见都回到editor手里，他们会考虑11天的时间，所以意见回到我手上是一个半月以后），revised重新投回去后，第二次review只等了14天，所有的意见都回到了editor手里，他们讨论了11天后才把意见返回到我手上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=774, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Dec 26 20:11:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485168, encodeId=077a48516849, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：If my problem was a Death Star, this atrlcie is a photon torpedo., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=695, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Tessa, createdTime=Mon Oct 31 18:14:00 CST 2011, time=2011-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483892, encodeId=4187483892e7, content=very difficult, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 09 22:08:00 CST 2011, time=2011-08-09, status=1, ipAttribution=)]

2020-06-29 qsqsqsqs12

22.5，超过NI了

293 0

[GetPortalCommentsPageByObjectIdResponse(id=2214044, encodeId=e6b62214044fc, content=投了9天还没消息是好消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb82411870, createdName=1237a2bem44(暂无昵称), createdTime=Tue Jul 09 11:35:03 CST 2024, time=2024-07-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1182151, encodeId=4eee1182151e9, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;感染;基础免疫 经验分享：免疫学研究型期刊大概如下：第一档，Cell，Nature，Science第二档，Cell子刊Immunity，这几年上升势头很快，IF也超过了Nature immunology；Nature子刊Nature immunology，这几年IF有所下降，不过不失为免疫性方向最好的期刊之一；Nature子刊Nature medicine，若有清楚的机制研究加上潜在的临床应用，最好的选择之一。反正老板投稿顺序倾向是除CNS外， Immunity > Nature immunology> Science Immunology 第三档，Journal of Experimental Medicine，老牌偏免疫学杂志，近来IF渐行渐低，但上面的文章可一点儿也不含糊，不过这两年也更多的接受其它医学领域的研究了；Nature子刊Nature Cell Biology，不过其更偏向于经典细胞生物学，偶有偏免疫方向文章；Journal of Clinical Investigation，医学研究的老牌杂志，及Science比较新的子刊Science Translational Medicine大概也在这个档中。另外，像Journal of Allergy and Clinical Immunology、Blood、Gastroenterology也是很有实力的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c65457430, createdName=linkends353, createdTime=Sat Jan 08 10:47:10 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091785, encodeId=eddd1091e85ad, content=一般方法中要求写什么东西？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091786, encodeId=bf181091e86a9, content=一般情况下使用什么统计方法？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800296, encodeId=e986800296f2, content=22.5，超过NI了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:39:08 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=556195, encodeId=116455619575, content=Cell子刊.免疫学大佬.很难.不过感觉有些组做上手了后还是发了很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e502075746, createdName=营养医师, createdTime=Fri May 18 22:05:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544479, encodeId=49855444e902, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500353, encodeId=5d975003536c, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：Immunity这个杂志比 C N S这三大杂志来得更客观些，更看重你的工作本身；只要你的工作确实够有新意并且数据比较系统，他们就会选择把你的文章送出去review，后面三个杂志很看重author的分量，如果没有找重量级的大牛挂名，就很难有review的机会。 我的文章在这个杂志的第一次review用了一个半月（第32天的时候，所有的reviewer意见都回到editor手里，他们会考虑11天的时间，所以意见回到我手上是一个半月以后），revised重新投回去后，第二次review只等了14天，所有的意见都回到了editor手里，他们讨论了11天后才把意见返回到我手上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=774, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Dec 26 20:11:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485168, encodeId=077a48516849, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：If my problem was a Death Star, this atrlcie is a photon torpedo., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=695, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Tessa, createdTime=Mon Oct 31 18:14:00 CST 2011, time=2011-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483892, encodeId=4187483892e7, content=very difficult, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 09 22:08:00 CST 2011, time=2011-08-09, status=1, ipAttribution=)]

2018-05-18 营养医师

Cell子刊.免疫学大佬.很难.不过感觉有些组做上手了后还是发了很多

125 0

[GetPortalCommentsPageByObjectIdResponse(id=2214044, encodeId=e6b62214044fc, content=投了9天还没消息是好消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb82411870, createdName=1237a2bem44(暂无昵称), createdTime=Tue Jul 09 11:35:03 CST 2024, time=2024-07-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1182151, encodeId=4eee1182151e9, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;感染;基础免疫 经验分享：免疫学研究型期刊大概如下：第一档，Cell，Nature，Science第二档，Cell子刊Immunity，这几年上升势头很快，IF也超过了Nature immunology；Nature子刊Nature immunology，这几年IF有所下降，不过不失为免疫性方向最好的期刊之一；Nature子刊Nature medicine，若有清楚的机制研究加上潜在的临床应用，最好的选择之一。反正老板投稿顺序倾向是除CNS外， Immunity > Nature immunology> Science Immunology 第三档，Journal of Experimental Medicine，老牌偏免疫学杂志，近来IF渐行渐低，但上面的文章可一点儿也不含糊，不过这两年也更多的接受其它医学领域的研究了；Nature子刊Nature Cell Biology，不过其更偏向于经典细胞生物学，偶有偏免疫方向文章；Journal of Clinical Investigation，医学研究的老牌杂志，及Science比较新的子刊Science Translational Medicine大概也在这个档中。另外，像Journal of Allergy and Clinical Immunology、Blood、Gastroenterology也是很有实力的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c65457430, createdName=linkends353, createdTime=Sat Jan 08 10:47:10 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091785, encodeId=eddd1091e85ad, content=一般方法中要求写什么东西？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091786, encodeId=bf181091e86a9, content=一般情况下使用什么统计方法？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800296, encodeId=e986800296f2, content=22.5，超过NI了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:39:08 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=556195, encodeId=116455619575, content=Cell子刊.免疫学大佬.很难.不过感觉有些组做上手了后还是发了很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e502075746, createdName=营养医师, createdTime=Fri May 18 22:05:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544479, encodeId=49855444e902, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500353, encodeId=5d975003536c, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：Immunity这个杂志比 C N S这三大杂志来得更客观些，更看重你的工作本身；只要你的工作确实够有新意并且数据比较系统，他们就会选择把你的文章送出去review，后面三个杂志很看重author的分量，如果没有找重量级的大牛挂名，就很难有review的机会。 我的文章在这个杂志的第一次review用了一个半月（第32天的时候，所有的reviewer意见都回到editor手里，他们会考虑11天的时间，所以意见回到我手上是一个半月以后），revised重新投回去后，第二次review只等了14天，所有的意见都回到了editor手里，他们讨论了11天后才把意见返回到我手上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=774, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Dec 26 20:11:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485168, encodeId=077a48516849, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：If my problem was a Death Star, this atrlcie is a photon torpedo., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=695, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Tessa, createdTime=Mon Oct 31 18:14:00 CST 2011, time=2011-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483892, encodeId=4187483892e7, content=very difficult, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 09 22:08:00 CST 2011, time=2011-08-09, status=1, ipAttribution=)]

2017-07-16 gu_8183

谁能预测明年会有多少分?

468 0

[GetPortalCommentsPageByObjectIdResponse(id=2214044, encodeId=e6b62214044fc, content=投了9天还没消息是好消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb82411870, createdName=1237a2bem44(暂无昵称), createdTime=Tue Jul 09 11:35:03 CST 2024, time=2024-07-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1182151, encodeId=4eee1182151e9, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;感染;基础免疫 经验分享：免疫学研究型期刊大概如下：第一档，Cell，Nature，Science第二档，Cell子刊Immunity，这几年上升势头很快，IF也超过了Nature immunology；Nature子刊Nature immunology，这几年IF有所下降，不过不失为免疫性方向最好的期刊之一；Nature子刊Nature medicine，若有清楚的机制研究加上潜在的临床应用，最好的选择之一。反正老板投稿顺序倾向是除CNS外， Immunity > Nature immunology> Science Immunology 第三档，Journal of Experimental Medicine，老牌偏免疫学杂志，近来IF渐行渐低，但上面的文章可一点儿也不含糊，不过这两年也更多的接受其它医学领域的研究了；Nature子刊Nature Cell Biology，不过其更偏向于经典细胞生物学，偶有偏免疫方向文章；Journal of Clinical Investigation，医学研究的老牌杂志，及Science比较新的子刊Science Translational Medicine大概也在这个档中。另外，像Journal of Allergy and Clinical Immunology、Blood、Gastroenterology也是很有实力的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c65457430, createdName=linkends353, createdTime=Sat Jan 08 10:47:10 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091785, encodeId=eddd1091e85ad, content=一般方法中要求写什么东西？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091786, encodeId=bf181091e86a9, content=一般情况下使用什么统计方法？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800296, encodeId=e986800296f2, content=22.5，超过NI了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:39:08 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=556195, encodeId=116455619575, content=Cell子刊.免疫学大佬.很难.不过感觉有些组做上手了后还是发了很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e502075746, createdName=营养医师, createdTime=Fri May 18 22:05:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544479, encodeId=49855444e902, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500353, encodeId=5d975003536c, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：Immunity这个杂志比 C N S这三大杂志来得更客观些，更看重你的工作本身；只要你的工作确实够有新意并且数据比较系统，他们就会选择把你的文章送出去review，后面三个杂志很看重author的分量，如果没有找重量级的大牛挂名，就很难有review的机会。 我的文章在这个杂志的第一次review用了一个半月（第32天的时候，所有的reviewer意见都回到editor手里，他们会考虑11天的时间，所以意见回到我手上是一个半月以后），revised重新投回去后，第二次review只等了14天，所有的意见都回到了editor手里，他们讨论了11天后才把意见返回到我手上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=774, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Dec 26 20:11:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485168, encodeId=077a48516849, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：If my problem was a Death Star, this atrlcie is a photon torpedo., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=695, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Tessa, createdTime=Mon Oct 31 18:14:00 CST 2011, time=2011-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483892, encodeId=4187483892e7, content=very difficult, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 09 22:08:00 CST 2011, time=2011-08-09, status=1, ipAttribution=)]

2013-12-26 匿名用户

审稿速度:2.0 | 投稿命中率:5.0
经验分享：Immunity这个杂志比 C N S这三大杂志来得更客观些，更看重你的工作本身；只要你的工作确实够有新意并且数据比较系统，他们就会选择把你的文章送出去review，后面三个杂志很看重author的分量，如果没有找重量级的大牛挂名，就很难有review的机会。
我的文章在这个杂志的第一次review用了一个半月（第32天的时候，所有的reviewer意见都回到editor手里，他们会考虑11天的时间，所以意见回到我手上是一个半月以后），revised重新投回去后，第二次review只等了14天，所有的意见都回到了editor手里，他们讨论了11天后才把意见返回到我手上。

774 0

[GetPortalCommentsPageByObjectIdResponse(id=2214044, encodeId=e6b62214044fc, content=投了9天还没消息是好消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb82411870, createdName=1237a2bem44(暂无昵称), createdTime=Tue Jul 09 11:35:03 CST 2024, time=2024-07-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1182151, encodeId=4eee1182151e9, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;感染;基础免疫 经验分享：免疫学研究型期刊大概如下：第一档，Cell，Nature，Science第二档，Cell子刊Immunity，这几年上升势头很快，IF也超过了Nature immunology；Nature子刊Nature immunology，这几年IF有所下降，不过不失为免疫性方向最好的期刊之一；Nature子刊Nature medicine，若有清楚的机制研究加上潜在的临床应用，最好的选择之一。反正老板投稿顺序倾向是除CNS外， Immunity > Nature immunology> Science Immunology 第三档，Journal of Experimental Medicine，老牌偏免疫学杂志，近来IF渐行渐低，但上面的文章可一点儿也不含糊，不过这两年也更多的接受其它医学领域的研究了；Nature子刊Nature Cell Biology，不过其更偏向于经典细胞生物学，偶有偏免疫方向文章；Journal of Clinical Investigation，医学研究的老牌杂志，及Science比较新的子刊Science Translational Medicine大概也在这个档中。另外，像Journal of Allergy and Clinical Immunology、Blood、Gastroenterology也是很有实力的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c65457430, createdName=linkends353, createdTime=Sat Jan 08 10:47:10 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091785, encodeId=eddd1091e85ad, content=一般方法中要求写什么东西？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091786, encodeId=bf181091e86a9, content=一般情况下使用什么统计方法？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800296, encodeId=e986800296f2, content=22.5，超过NI了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:39:08 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=556195, encodeId=116455619575, content=Cell子刊.免疫学大佬.很难.不过感觉有些组做上手了后还是发了很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e502075746, createdName=营养医师, createdTime=Fri May 18 22:05:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544479, encodeId=49855444e902, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500353, encodeId=5d975003536c, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：Immunity这个杂志比 C N S这三大杂志来得更客观些，更看重你的工作本身；只要你的工作确实够有新意并且数据比较系统，他们就会选择把你的文章送出去review，后面三个杂志很看重author的分量，如果没有找重量级的大牛挂名，就很难有review的机会。 我的文章在这个杂志的第一次review用了一个半月（第32天的时候，所有的reviewer意见都回到editor手里，他们会考虑11天的时间，所以意见回到我手上是一个半月以后），revised重新投回去后，第二次review只等了14天，所有的意见都回到了editor手里，他们讨论了11天后才把意见返回到我手上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=774, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Dec 26 20:11:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485168, encodeId=077a48516849, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：If my problem was a Death Star, this atrlcie is a photon torpedo., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=695, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Tessa, createdTime=Mon Oct 31 18:14:00 CST 2011, time=2011-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483892, encodeId=4187483892e7, content=very difficult, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 09 22:08:00 CST 2011, time=2011-08-09, status=1, ipAttribution=)]

2011-10-31 Tessa

审稿速度:6.0 | 投稿命中率:50.0
经验分享：If my problem was a Death Star, this atrlcie is a photon torpedo.

695 0

[GetPortalCommentsPageByObjectIdResponse(id=2214044, encodeId=e6b62214044fc, content=投了9天还没消息是好消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb82411870, createdName=1237a2bem44(暂无昵称), createdTime=Tue Jul 09 11:35:03 CST 2024, time=2024-07-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1182151, encodeId=4eee1182151e9, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;感染;基础免疫 经验分享：免疫学研究型期刊大概如下：第一档，Cell，Nature，Science第二档，Cell子刊Immunity，这几年上升势头很快，IF也超过了Nature immunology；Nature子刊Nature immunology，这几年IF有所下降，不过不失为免疫性方向最好的期刊之一；Nature子刊Nature medicine，若有清楚的机制研究加上潜在的临床应用，最好的选择之一。反正老板投稿顺序倾向是除CNS外， Immunity > Nature immunology> Science Immunology 第三档，Journal of Experimental Medicine，老牌偏免疫学杂志，近来IF渐行渐低，但上面的文章可一点儿也不含糊，不过这两年也更多的接受其它医学领域的研究了；Nature子刊Nature Cell Biology，不过其更偏向于经典细胞生物学，偶有偏免疫方向文章；Journal of Clinical Investigation，医学研究的老牌杂志，及Science比较新的子刊Science Translational Medicine大概也在这个档中。另外，像Journal of Allergy and Clinical Immunology、Blood、Gastroenterology也是很有实力的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c65457430, createdName=linkends353, createdTime=Sat Jan 08 10:47:10 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091785, encodeId=eddd1091e85ad, content=一般方法中要求写什么东西？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091786, encodeId=bf181091e86a9, content=一般情况下使用什么统计方法？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800296, encodeId=e986800296f2, content=22.5，超过NI了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Mon Jun 29 18:39:08 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=556195, encodeId=116455619575, content=Cell子刊.免疫学大佬.很难.不过感觉有些组做上手了后还是发了很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e502075746, createdName=营养医师, createdTime=Fri May 18 22:05:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544479, encodeId=49855444e902, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=468, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500353, encodeId=5d975003536c, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：Immunity这个杂志比 C N S这三大杂志来得更客观些，更看重你的工作本身；只要你的工作确实够有新意并且数据比较系统，他们就会选择把你的文章送出去review，后面三个杂志很看重author的分量，如果没有找重量级的大牛挂名，就很难有review的机会。 我的文章在这个杂志的第一次review用了一个半月（第32天的时候，所有的reviewer意见都回到editor手里，他们会考虑11天的时间，所以意见回到我手上是一个半月以后），revised重新投回去后，第二次review只等了14天，所有的意见都回到了editor手里，他们讨论了11天后才把意见返回到我手上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=774, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Dec 26 20:11:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485168, encodeId=077a48516849, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：If my problem was a Death Star, this atrlcie is a photon torpedo., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=695, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Tessa, createdTime=Mon Oct 31 18:14:00 CST 2011, time=2011-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483892, encodeId=4187483892e7, content=very difficult, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 09 22:08:00 CST 2011, time=2011-08-09, status=1, ipAttribution=)]

2011-08-09 匿名用户

very difficult

749 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务